Ovarian Hyperstimulation Syndrome and Cabergoline
Launched by ETLIK ZUBEYDE HANIM WOMENS' HEALTH AND TEACHING HOSPITAL · Apr 2, 2012
Trial Information
Current as of June 25, 2025
Completed
Keywords
ClinConnect Summary
Dopamine agonists have been proposed as a prophylactic treatment for OHSS in women with high risk of OHSS, however the possible mechanism of action has not been clearly known. In experimental studies, inhibition of vascular endothelial growth factor based pathway was proposed as a possible action of mechanism of dopamine agonists. However the role hepatocyte growth factor (HGF), insulin like growth factor-I (IGF-I), inhibin B and antimullerian hormone (AMH) on cabergoline action in OHSS prevention has not been known.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Development of more than 14 leading follicles larger than 10 mm and serum estradiol more than 3000 pg/ml at the end of ovulation induction with long luteal ovulation induction protocol.
- • Having the criteria of PCOS
- Exclusion Criteria:
- • Not having the inclusion criteria.
About Etlik Zubeyde Hanim Womens' Health And Teaching Hospital
Etlik Zubeyde Hanım Women's Health and Teaching Hospital is a leading healthcare institution dedicated to advancing women's health through innovative clinical research and education. With a strong emphasis on evidence-based practices, the hospital serves as a pivotal center for conducting clinical trials aimed at improving health outcomes for women. Committed to high ethical standards and patient safety, the hospital collaborates with a multidisciplinary team of experts to foster groundbreaking research initiatives that address the unique healthcare needs of women, ultimately contributing to the enhancement of women's health services both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Emine Seda Guvendag Guven, MD
Study Chair
Rize University, Faculty of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials